NO20060686L - Fremgangsmate for behandling eller hindring av forstyrrelser i sentralnervesystemet med forbindelser som er selektive for alfa 3 subenhet til benzodiazepinreseptor - Google Patents
Fremgangsmate for behandling eller hindring av forstyrrelser i sentralnervesystemet med forbindelser som er selektive for alfa 3 subenhet til benzodiazepinreseptorInfo
- Publication number
- NO20060686L NO20060686L NO20060686A NO20060686A NO20060686L NO 20060686 L NO20060686 L NO 20060686L NO 20060686 A NO20060686 A NO 20060686A NO 20060686 A NO20060686 A NO 20060686A NO 20060686 L NO20060686 L NO 20060686L
- Authority
- NO
- Norway
- Prior art keywords
- nervous system
- central nervous
- subunit
- alpha
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48667803P | 2003-07-11 | 2003-07-11 | |
| PCT/EP2004/006989 WO2005004867A2 (en) | 2003-07-11 | 2004-06-28 | Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20060686L true NO20060686L (no) | 2006-03-14 |
Family
ID=34062138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060686A NO20060686L (no) | 2003-07-11 | 2006-02-13 | Fremgangsmate for behandling eller hindring av forstyrrelser i sentralnervesystemet med forbindelser som er selektive for alfa 3 subenhet til benzodiazepinreseptor |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050032863A1 (xx) |
| EP (2) | EP1646386A2 (xx) |
| JP (1) | JP2009513539A (xx) |
| KR (1) | KR20060032633A (xx) |
| CN (2) | CN1822836A (xx) |
| AR (1) | AR045013A1 (xx) |
| AU (1) | AU2004255414A1 (xx) |
| BR (1) | BRPI0412512A (xx) |
| CA (1) | CA2531861A1 (xx) |
| MX (1) | MXPA05013196A (xx) |
| NO (1) | NO20060686L (xx) |
| NZ (1) | NZ544251A (xx) |
| RU (1) | RU2354377C2 (xx) |
| TW (1) | TW200512197A (xx) |
| UA (1) | UA87982C2 (xx) |
| WO (1) | WO2005004867A2 (xx) |
| ZA (1) | ZA200509169B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007222446B2 (en) * | 2006-03-08 | 2011-08-18 | F. Hoffmann-La Roche Ag | 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones |
| EP2473055A4 (en) | 2009-09-04 | 2013-02-13 | Univ Vanderbilt | ALLOSTERIC MGLUR4 POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| AU2012296925A1 (en) | 2011-08-12 | 2014-02-06 | Boehringer Ingelheim Vetmedica Gmbh | Taste masked pharmaceutical composition |
| CN104199105A (zh) * | 2014-08-27 | 2014-12-10 | 中国石油天然气集团公司 | 高密度三维勘探中初至的拾取方法及拾取装置 |
| WO2018011566A1 (en) * | 2016-07-11 | 2018-01-18 | Ranvier Health Limited | Method of diagnostic relevance based on taste recognition |
| AU2020326244A1 (en) * | 2019-08-06 | 2022-03-17 | Initiator Pharma A/S | Compound for combination treatment |
| KR102489109B1 (ko) * | 2020-06-02 | 2023-01-16 | 부산대학교 산학협력단 | 아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI90869C (fi) * | 1986-11-14 | 1994-04-11 | Tanabe Seiyaku Co | Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi |
| AU5884696A (en) | 1995-06-23 | 1997-01-22 | Bausch & Lomb Incorporated | Method for cleaning contact lenses utilizing polysulfonates |
| DE19532668A1 (de) * | 1995-09-05 | 1997-03-06 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung |
| US5869481A (en) * | 1995-09-05 | 1999-02-09 | Arzneitmittelwerk Dresden G.M.B.H. | Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making |
| US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| DE19721580A1 (de) * | 1997-05-23 | 1998-11-26 | Dresden Arzneimittel | Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen |
| WO1999037370A1 (en) | 1998-01-22 | 1999-07-29 | Precedence Publishing, Inc. | Game using collectibles as playing pieces |
| GB9821179D0 (en) | 1998-09-30 | 1998-11-25 | Merck Sharp & Dohme | Therapeutic use |
| GB9929687D0 (en) | 1999-12-15 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| GB0122696D0 (en) * | 2001-09-20 | 2001-11-14 | Merck Sharp & Dohme | Therapeutic agents |
| US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
-
2004
- 2004-06-28 JP JP2006519793A patent/JP2009513539A/ja not_active Withdrawn
- 2004-06-28 BR BRPI0412512-6A patent/BRPI0412512A/pt not_active IP Right Cessation
- 2004-06-28 EP EP04740387A patent/EP1646386A2/en not_active Withdrawn
- 2004-06-28 CA CA002531861A patent/CA2531861A1/en not_active Abandoned
- 2004-06-28 AU AU2004255414A patent/AU2004255414A1/en not_active Abandoned
- 2004-06-28 WO PCT/EP2004/006989 patent/WO2005004867A2/en active Application Filing
- 2004-06-28 CN CNA2004800199698A patent/CN1822836A/zh active Pending
- 2004-06-28 UA UAA200600251A patent/UA87982C2/ru unknown
- 2004-06-28 US US10/878,987 patent/US20050032863A1/en not_active Abandoned
- 2004-06-28 KR KR1020067000739A patent/KR20060032633A/ko not_active Application Discontinuation
- 2004-06-28 MX MXPA05013196A patent/MXPA05013196A/es unknown
- 2004-06-28 RU RU2006104118/14A patent/RU2354377C2/ru not_active IP Right Cessation
- 2004-06-28 NZ NZ544251A patent/NZ544251A/en unknown
- 2004-06-28 CN CNA200710169458XA patent/CN101254189A/zh active Pending
- 2004-06-28 EP EP08168609A patent/EP2027856A1/en not_active Withdrawn
- 2004-06-29 TW TW093119215A patent/TW200512197A/zh unknown
- 2004-07-02 AR ARP040102355A patent/AR045013A1/es unknown
-
2005
- 2005-11-14 ZA ZA200509169A patent/ZA200509169B/xx unknown
-
2006
- 2006-02-13 NO NO20060686A patent/NO20060686L/no not_active Application Discontinuation
-
2007
- 2007-10-29 US US11/978,362 patent/US20080114032A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| UA87982C2 (ru) | 2009-09-10 |
| WO2005004867A2 (en) | 2005-01-20 |
| US20050032863A1 (en) | 2005-02-10 |
| WO2005004867A3 (en) | 2005-04-21 |
| BRPI0412512A (pt) | 2006-09-19 |
| AR045013A1 (es) | 2005-10-12 |
| CA2531861A1 (en) | 2005-01-20 |
| RU2354377C2 (ru) | 2009-05-10 |
| AU2004255414A1 (en) | 2005-01-20 |
| US20080114032A1 (en) | 2008-05-15 |
| CN1822836A (zh) | 2006-08-23 |
| NZ544251A (en) | 2009-12-24 |
| CN101254189A (zh) | 2008-09-03 |
| JP2009513539A (ja) | 2009-04-02 |
| ZA200509169B (en) | 2006-07-26 |
| EP2027856A1 (en) | 2009-02-25 |
| MXPA05013196A (es) | 2006-03-09 |
| TW200512197A (en) | 2005-04-01 |
| KR20060032633A (ko) | 2006-04-17 |
| EP1646386A2 (en) | 2006-04-19 |
| RU2006104118A (ru) | 2006-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060686L (no) | Fremgangsmate for behandling eller hindring av forstyrrelser i sentralnervesystemet med forbindelser som er selektive for alfa 3 subenhet til benzodiazepinreseptor | |
| BR0314059A (pt) | Compostos heterocìclicos | |
| BR0314393A (pt) | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia | |
| AR035722A1 (es) | Derivados de indol, procesos para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la produccion de medicamentos | |
| ATE349985T1 (de) | Nasenunterstützungsvorrichtung für haussäugetiere und verwendung | |
| ECSP066336A (es) | Derivados de 3-amino croman y 2-amino tetralin | |
| BR0114552A (pt) | N1- (benzenosulfonil) indóis 2-,3-,4-, 5- substituìdos e seu uso em terapia | |
| CL2010001173A1 (es) | Compuestos derivados de 1,4-diazepam sustituido, antagonistas de ox1 y ox2; utiles para preparar un medicamento destinado al tratamiento o prevencion de un trastorno del sueño,para potenciar la calidad del sueno,y para tratar o controlar la obesidad.(divisional de la sol.n 3441-07) | |
| ATE486600T1 (de) | Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5 | |
| NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
| ATE160779T1 (de) | Antipsychotische indazolderivate | |
| BRPI0415769A (pt) | alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as | |
| DK1924560T3 (da) | 6-substituerede-2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C-receptoragonister | |
| NO20082679L (no) | Sammensetning og fremgangsmate for a behandle CNS lidelser | |
| AR028705A1 (es) | Bis-arilsulfonas | |
| ES2150671T3 (es) | Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a. | |
| BRPI0409436A (pt) | compostos de 4-fenil-piperidina e a sua utilização como moduladores de receptores de opióides | |
| NO20015247L (no) | Glysinspaltingssysteminhibitorer som potensielle antipsykotika | |
| DE60033310D1 (de) | Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung | |
| CL2008000904A1 (es) | Compuestos derivados de azabiciclo [3.3.0]octenos y azabiciclo[3.3.1]nonanos sustituidos, con la alta afinidad a receptores nicotinicos de subtipo alfa4beta2 en el sistema nervioso central; composicion farmaceutica; y su uso en el tratamiento del deterioro de la memorias asociado a la edad, deterioro cognitivo leve, demencia senil, entre otras. | |
| CY1107437T1 (el) | Νεα πολυπεπτιδια kcnq και οι χρησεις τους στη διαγνωση διανοητικων διαταραχων | |
| CL2008001158A1 (es) | Compuestos derivados de (piperidin-4-il)-([1,3,4]tiadiazol-2-il)-amina o (piperidin-4-il)-(tiazol-2-il)-amina, antagonistas del receptor de dopamina d2; composiciones farmaceuticas que los contienen; y su uso en la prevencion y tratamiento de enfermedades del snc tales como la esquizofrenia. | |
| DE60325865D1 (de) | Phenylpyridazin derivative als liganden für gaba-rezeptoren | |
| BRPI0415793A (pt) | processo para a oxidação de ciclohexano | |
| BR0112131A (pt) | Composições farmacêuticas e métodos para uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |